A strategic move or a ploy to arrest further shareholder wealth erosion?
08/07/24 -"The Grifols family and Brookfield have agreed to take Grifols private and should submit the bid in the coming weeks. This comes at an opportune time for the controlling shareholders since the shares ..."
Pages
54
Language
English
Published on
08/07/24
You may also be interested by these reports :
30/10/26
Investors hailed the Q3 profitability beat and the announcement of a cost savings initiative. The generic erosion of some CVRM medicines was ...
30/10/26
The Q3 beat was impressive and a guidance upgrade to boot cheered up investors. As usual, the all-important immunology medicine Dupixent remained a ...
29/10/26
The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s ...
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...